Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

53.81 +11.18 (+26.24%)
Streaming Delayed Price Updated: 9:53 AM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis reports second quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold second quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
From Biogen Inc.
Via GlobeNewswire
Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
From Biogen Inc.
Via GlobeNewswire
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
From Ionis Pharmaceuticals, Inc.
Via Business Wire
First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to host 2025 virtual Annual Meeting of Stockholders
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis reports first quarter 2025 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold first quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to host expert panel discussion on sHTG
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
From Ionis Pharmaceuticals, Inc.
Via Business Wire
WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis reports fourth quarter and full year 2024 financial results
From Ionis Pharmaceuticals, Inc.
Via Business Wire
Ionis to hold fourth quarter and full year 2024 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA 
From Biogen Inc.
Via GlobeNewswire
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
From Biogen Inc.
Via GlobeNewswire
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.